On June 14, 2024, Hopstem was voted first place out of 20 pitching teams by a panel of top investors and pharmaceutical executives, virtually at the 2024 annual SAPA Investment Forum and online Road Show. Hopstem’s breakthrough allogeneic iPSC-derived hNPC01 cell therapy has demonstrated good safety and sign of efficacy in chronic stroke patients in the on-going phase I study, targeting more than 21 million global patients.
The Sino-American Pharmaceutical Professionals Association (SAPA), headquartered in New Jersey, is one of the most active Chinese professional associations in the US with more than 6,000 member.（https://www.sapaweb.org/hifnr-2024）
Mechanism study of hNPC01 neural progenitor cell grafting therapy in a rat ischemic stroke model was published in Nature Communications
Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke
Hopstem Biotechnology at 2024 CASSS CGPT Symposium
Hopstem Biotechnology to Participate in the 2024 BIO International Convention in San Diego
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
